StemSynergy Therapeutics’ Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells
StemSynergy Therapeutics, Inc., who collaborated on this study holds worldwide exclusivity to develop these molecules for the clinic.\n"The Notch pathway is an extremely attractive target for cancer therapeutics, as it is a critical driver of many human cancers.
- StemSynergy Therapeutics, Inc., who collaborated on this study holds worldwide exclusivity to develop these molecules for the clinic.\n"The Notch pathway is an extremely attractive target for cancer therapeutics, as it is a critical driver of many human cancers.
- "Specifically, NADI-351 clears cancer stem cells by starving them of Notch signaling and causes cell death in tumors, including esophageal and triple-negative breast cancer.
- At the same time this breakthrough science is being published, StemSynergy Therapeutics is developing this class of compound for clinical evaluation.
- Our mission is to optimize efficacy against the pathways required to drive cancer stem cells, such as the Wnt, Sonic Hedgehog and Notch signaling pathways.